Patents Examined by Robert C. Hayes
  • Method of treating intraoccular tissue pathologies with nerve growth factor
    Patent number: 9345749
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: May 24, 2016
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventor: Alessandro Lambiase
  • Post-translationally modified neurotrophin antibodies
    Patent number: 9328163
    Abstract: The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that bind to these modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving chronic pain and/or neuron loss.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 3, 2016
    Assignees: INSTITUT PASTEUR, INSTITUTO DE INVESTIGACIONES BIOLOGICAS CLEMENTE ESTABLE, FACULTAD DE MEDICINA, UNIVERSIDAD DE LA REPUBLICA, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Luis Barbeito, Mariana Pehar, Patricia Cassina, Pedro M. Alzari
  • Specific binding members for NGF
    Patent number: 9315571
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: April 19, 2016
    Assignees: Elan Pharma International Limited, MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • Benzoic acid amide compound
    Patent number: 9254251
    Abstract: The present invention relates to a novel benzoic acid amide derivative compound, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof, or solvates thereof. The novel compound has excellent skin whitening effects.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 9, 2016
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Yung Hyup Joo, Heung Soo Baek, Chang Seok Lee, Soo Jeong Choi, Ho Sik Rho, Mi Young Park, Song Seok Shin, Kyung Min Lim, Young Ho Park
  • Stable solid deodorant product and method of manufacturing same
    Patent number: 9247800
    Abstract: The present invention provides a deodorant formulation having improved efficacy and stability. The deodorant formulation comprises propanediol, ethylhexylglycerin, and grapefruit seed extract as the principal deodorizing actives. The combination of these deodorizing active ingredients results in a formulation with strong efficacy. The deodorant formulation of the invention may further be formed into a stable solid stick product in accordance with the methods outlined herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 2, 2016
    Assignee: Knowlton Development Corporation Inc
    Inventor: Hany Abo-El-Magd Mobarak
  • Variants of human GDNF
    Patent number: 9243046
    Abstract: The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: January 26, 2016
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jirong Lu, Kalpana Mahesh Merchant, Mahmoud Ghanem, Linda Maureen O'Bryan, Rosamund Carol Smith
  • Treatment methods for hypersensitive disorders
    Patent number: 9233140
    Abstract: The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: January 12, 2016
    Assignee: Promedior, Inc.
    Inventor: Lynne Anne Murray
  • Methods and kits for detecting misfolded proteins
    Patent number: 9229009
    Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: January 5, 2016
    Assignees: Yale University, The Regents of the University of California
    Inventors: Catalin S. Buhimschi, Irina Buhimschi, Charles G. Glabe
  • Method of treating pain with anti-human NGF antibody
    Patent number: 9127055
    Abstract: Anti-human NGF antibodies are useful for treating pain.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: September 8, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
  • Microbial-derived chondroitin sulfate
    Patent number: 9109243
    Abstract: Described is chondroitin sulfate obtained from microbial sources, and related compositions and methods.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: August 18, 2015
    Assignees: AMANO ENZYME USA, LTD., AMANO ENZYME, INC.
    Inventors: James F. Jolly, Krzysztof Klimaszewski, Yuji Nakanishi, Hirotaka Matsubara, Tetsuya Takahashi, Kyouichi Nishio
  • Methods for renal denervation
    Patent number: 9056184
    Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: June 16, 2015
    Assignee: Northwind Medical, Inc.
    Inventors: Emily A. Stein, Kondapavulur T. Venkateswara-Rao, Michael A. Evans
  • Hepatocyte growth factor mimics as therapeutic agents
    Patent number: 9051351
    Abstract: Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia (e.g. Alzheimer's) and Parkinson's disease.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 9, 2015
    Assignee: Washington State University
    Inventors: Joseph W. Harding, John W. Wright, Caroline C. Benoist, Leen H. Kawas, Gary A. Wayman
  • Methods of treating stroke using stem cell-like menstrual blood cells
    Patent number: 9044431
    Abstract: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: June 2, 2015
    Assignees: University of South Florida, Medical College of Georgia, Cryo-Cell International, Inc.
    Inventors: Paul R. Sanberg, Cesario V. Borlongan, Julie Allickson
  • Neurturin conjugates for pharmaceutical use
    Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Treatment of astrocytes-tumor cells inhibitors of endothelin receptors
    Patent number: 8999934
    Abstract: The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: April 7, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Isaiah Fidler, Sun-jin Kim
  • Anti-human NGF antibody
    Patent number: 8986952
    Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 24, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
  • Methods for renal denervation
    Patent number: 8975233
    Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: March 10, 2015
    Assignee: Northwind Medical, Inc.
    Inventors: Emily A. Stein, Kondapavulur T. Venkateswara-Rao, Michael A. Evans
  • Therapeutic use of the encoding sequence of the carboxy-terminal domain of the heavy chain of the tetanus toxin
    Patent number: 8945586
    Abstract: The present invention relates to the therapeutic use of the carboxy-terminal domain of the heavy chain of the tetanus toxin for the treatment of amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: February 3, 2015
    Assignees: University of Zaragoza, Autonomous University of Barcelona
    Inventors: María Moreno Igoa, Ana Cristina Calvo Royo, Maria Jesús Muñoz Gonzalvo, Maria Pilar Zaragoza Fernández, Rosario Osta Pinzolas, José Aguilera Avila
  • Antibodies directed against nerve growth factor (NGF)
    Patent number: 8926978
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 6, 2015
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
  • Polynucleotides encoding humanized anti-NGF antibodies
    Patent number: 8877491
    Abstract: Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Antonino Cattaneo, Doriano Lamba, Sonia Covaceuszach